Oncology Archives - Page 14 of 23

Early engagement of the “patient voice” to inform patient reported outcome measurement in global pivotal trial of Cholangiocarcinoma

Authors: E Boxell, J Bernarde, E Rzepa, L Baldock, A J Rylands Published: Value in health, 2018 View publication Objectives Regulatory authorities (e.g. FDA, EMA) endorse initiation of partnerships with patients in...

An assessment of Patient Reported Outcome (PRO) clinical trial data reporting, specific to Cholangiocarcinoma (CCA)

Authors: J Bernarde; E Boxell, L Baldock; AJ Rylands Published: Value in health, 2018 View publication Objectives Patient reported outcome (PRO) data from clinical trials are often underreported or reported inconsistently (Calvert...

Quality of Life and ability to work in patients at different disease stages of HER2+ breast cancer

Authors: M Verrill, AM Wardley, J Retzler, AB Smith, D McNicol, S Dando, I Tran, I Leslie, P Schmid Published: American Association for Cancer Research, 2017 View publication Objectives Health-related quality of...

The TARGET UK Study: real-world evidence of molecular response to tyrosine kinase inhibitors supports European LeukemiaNet 2013 recommendations for the management of Chronic Myeloid Leukaemia

Authors: D Milojkovic, R Clark, J Byrne, B Huntly, M Raghavan, F Wandroo, S Ali, B Austen, J Ryan, K Friedrich, N C P Cross, A Mead Published: Blood, 2017 View publication...

The incidence, diagnostic pathway and management of pulmonary carcinoid tumours in the UK: Results from the National Lung NET pathway (‘LEAP’) Project

Authors: W Mansoor, S Ferguson, D Talbot Published: 2018 View publication

The missing malignancies – follow-up of patients with pulmonary carcinoid tumours in the UK: Results from the National Lung NET Pathway (LEAP) Project

Authors: W Mansoor, S Ferguson, D Talbot Published: Endocrine Abstracts, 2017 View publication Introduction Close long-term follow-up of patients with pulmonary carcinoid (PC) tumours is important for detection of recurrence, which can...

Inferior Clinical Outcomes With Fixed-Duration Therapy for Transplant-Ineligible Myeloma Patients: UK Real-World Datain Comparison With the FIRST Trial (MM-020)

Authors: F Sharpley, F Djebbari, S Fourali, J Kothari, J Lynes, S McLain-Smith, K Ramasamy Published: Blood, 2017 View publication Background Continuous therapy for patients with transplant-ineligible (TNE) newly diagnosed multiple myeloma...

Age (≤75 years) and Not Choice of First-line Therapy Improves Overall Survival in Transplant Ineligible NDMM Patients: Results from a Large UK Real-World Dataset

Authors: F Djebbari, F A Sharpley, C Sweeney, S Fourali, G Vallance, A Peniket, L Ferguson, S McLain-Smith, J Kothari, K Ramasamy Published: Blood, 2017 View publication Background UK standard of care...

End of life secondary care resource use and costs in mycosis fungoides and Sézary Syndrome: An analysis of hospital episode statistics

Authors: N Muszbek, F Glen, D Heaton, L McNamara Published: Value in Health, 2020 View publication Introduction Cutaneous T-cell lymphomas (CTCL) are a rare heterogeneous sub-group of non-Hodgkin’s lymphomas with debilitating consequences....

News